İÇLİ, F. Et Al. 2015. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG). BREAST CANCER , vol.22, no.5 , 480-485.

İÇLİ, F., Altundag, K., AKBULUT, H., PAYDAŞ, S., BAŞARAN, G., Saip, P., ... GÖKÖZ DOĞU, G.(2015). Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG). BREAST CANCER , vol.22, no.5, 480-485.

İÇLİ, FİKRİ Et Al. "Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)," BREAST CANCER , vol.22, no.5, 480-485, 2015

İÇLİ, FİKRİ Et Al. "Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)." BREAST CANCER , vol.22, no.5, pp.480-485, 2015

İÇLİ, F. Et Al. (2015) . "Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)." BREAST CANCER , vol.22, no.5, pp.480-485.

@article{article, author={FİKRİ İÇLİ Et Al. }, title={Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)}, journal={BREAST CANCER}, year=2015, pages={480-485} }